TOI vs. PTWO, SHLT, SHOT, LTRN, VHAQ, TSBX, PDEX, ALRN, FHLT, and NVNO
Should you be buying Oncology Institute stock or one of its competitors? The main competitors of Oncology Institute include Pono Capital Two (PTWO), SHL Telemedicine (SHLT), Safety Shot (SHOT), Lantern Pharma (LTRN), Viveon Health Acquisition (VHAQ), Turnstone Biologics (TSBX), Pro-Dex (PDEX), Aileron Therapeutics (ALRN), Future Health ESG (FHLT), and enVVeno Medical (NVNO). These companies are all part of the "medical" sector.
Oncology Institute (NASDAQ:TOI) and Pono Capital Two (NASDAQ:PTWO) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, valuation, community ranking, profitability, institutional ownership, media sentiment, analyst recommendations, risk and dividends.
Oncology Institute received 4 more outperform votes than Pono Capital Two when rated by MarketBeat users.
36.9% of Oncology Institute shares are owned by institutional investors. Comparatively, 60.8% of Pono Capital Two shares are owned by institutional investors. 9.5% of Oncology Institute shares are owned by insiders. Comparatively, 63.9% of Pono Capital Two shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Pono Capital Two has lower revenue, but higher earnings than Oncology Institute.
Pono Capital Two has a net margin of 0.00% compared to Oncology Institute's net margin of -20.28%. Pono Capital Two's return on equity of -6.63% beat Oncology Institute's return on equity.
Oncology Institute has a beta of 0.82, suggesting that its stock price is 18% less volatile than the S&P 500. Comparatively, Pono Capital Two has a beta of 0.01, suggesting that its stock price is 99% less volatile than the S&P 500.
Oncology Institute currently has a consensus target price of $2.25, suggesting a potential upside of 252.11%. Given Oncology Institute's higher probable upside, equities analysts clearly believe Oncology Institute is more favorable than Pono Capital Two.
In the previous week, Oncology Institute had 13 more articles in the media than Pono Capital Two. MarketBeat recorded 17 mentions for Oncology Institute and 4 mentions for Pono Capital Two. Pono Capital Two's average media sentiment score of 0.32 beat Oncology Institute's score of -0.58 indicating that Pono Capital Two is being referred to more favorably in the news media.
Summary
Pono Capital Two beats Oncology Institute on 7 of the 13 factors compared between the two stocks.
Get Oncology Institute News Delivered to You Automatically
Sign up to receive the latest news and ratings for TOI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TOI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Oncology Institute Competitors List
Related Companies and Tools
